stocks logo

BYSI

Beyondspring Inc
$
2.180
-0.02(-0.909%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings
Line
Line
|
Candle
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
2.245
Open
2.200
VWAP
2.18
Vol
12.77K
Mkt Cap
87.89M
Low
2.160
Amount
27.83K
EV/EBITDA(TTM)
--
Total Shares
40.30M
EV
95.00M
EV/OCF(TTM)
--
P/S(TTM)
--
BeyondSpring Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to improve clinical outcomes for patients with high unmet medical needs. Its lead asset, Plinabulin, is in late-stage clinical development as an anti-cancer agent in non-small cell lung cancer (NSCLC) and a range of cancer indications. The Company’s mechanism of action as a dendritic cell maturation agent supports both anti-cancer activity and immune modulation, offering an approach to resensitizing tumors to checkpoint inhibitors. It also has a pipeline of immuno-oncology product candidates, BPI-002 program, which is based on an oral small molecule agent that increases T-cell co-stimulation; BPI-003 program, which is based on a small molecule inhibitor of IKK, a protein kinase, and BPI-004 program, which is focused on a small molecule that induces the production of neo-antigens by tumor cells, allowing tumors containing no immune cells to be infiltrated by the immune system.
Show More

Valuation Metrics

The current forward P/E ratio for Beyondspring Inc (BYSI.O) is -6.88, compared to its 5-year average forward P/E of -3.24. For a more detailed relative valuation and DCF analysis to assess Beyondspring Inc 's fair value, click here.

Forward PE

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-3.24
Current PE
-6.88
Overvalued PE
-0.91
Undervalued PE
-5.57

Forward EV/EBITDA

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-1.63
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.89
Undervalued EV/EBITDA
-4.16

Forward PS

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
32.64
Current PS
0.44
Overvalued PS
84.51
Undervalued PS
-19.24

Financials

Annual
Quarterly
FY2025Q1
0.00
Total Revenue
FY2025Q1
-2.61M
Operating Profit
FY2025Q1
-2.58M
Net Income after Tax
FY2025Q1
0.11
EPS - Diluted
FY2025Q1
-4.25M
Free Cash Flow
FY2025Q1
N/A
Gross Profit Margin - %
FY2025Q1
N/A
FCF Margin - %
FY2025Q1
N/A
Net Margin - %

Trading Trends

Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months

BYSI News & Events

Events Timeline

2025-07-07 (ET)
2025-07-07
07:15:43
BeyondSpring announces publication of human clinical study on plinabulin
select
2025-06-03 (ET)
2025-06-03
07:04:00
BeyondSpring presents interim phase 2 data on 303 study
select
2025-03-27 (ET)
2025-03-27
07:11:56
BeyondSpring announces expected 2025 milestones
select
Sign Up For More Events

News

9.0
06-03Newsfilter
BeyondSpring Presents Efficacy/Safety Data from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at 2025 ASCO Annual Meeting
9.0
05-12NASDAQ.COM
BeyondSpring Inc. Reports Positive Early Results for Plinabulin in Metastatic Cancer and Updates on SEED Therapeutics' Progress
9.5
05-12Newsfilter
BeyondSpring Reports First‑Quarter 2025 Financial Results and Provides Corporate Update
Sign Up For More News

FAQ

arrow icon

What is Beyondspring Inc (BYSI) stock price today?

The current price of BYSI is 2.18 USD — it has decreased -0.91 % in the last trading day.

arrow icon

What is Beyondspring Inc (BYSI)'s business?

arrow icon

What is the price predicton of BYSI Stock?

arrow icon

What is Beyondspring Inc (BYSI)'s revenue for the last quarter?

arrow icon

What is Beyondspring Inc (BYSI)'s earnings per share (EPS) for the last quarter?

arrow icon

What changes have occurred in the market's expectations for Beyondspring Inc (BYSI)'s fundamentals?

arrow icon

How many employees does Beyondspring Inc (BYSI). have?

arrow icon

What is Beyondspring Inc (BYSI) market cap?